UK +44 (0)1865 849841
Malaysia +60 3 2117 5193
  • What does international collaboration mean for you?

    We asked three of our speakers what international collaboration means for them as leaders in their fields.

  • The Biosynthesis of Cannabinoids

    We spoke to Jeremy Friedberg, CSO of  LAVVAN, a company pioneering the biosynthesis of cannabinoids. 

  • The Grass Has Never Been Greener For Engineering Plant Immunity And Resilience

    The wide availability of sequencing technologies has been a rare step-change that has unlocked knowledge in a way nobody in the field could have imagined twenty years ago. Knowledge which could make a considerable contribution to food security in the face of changing climates.

  • How to beneficially modulate vaginal microbiota to optimise women’s health

    Vaginal microbiota plays a crucial role in women’s health and successful reproduction. However, we are just on the verge of discovering the full potential and features of this unique microbial community within women.

Discovering event sustainability in Brussels

“Our biggest challenge in this new century is to take an idea that seems abstract – sustainable development – and turn it into a reality ”

Kofi Annan

To try and turn an idea that seems abstract Global Engage has joined ISLA. This is a body that is working with the events industry to accelerate its transition to a sustainable future.

Read More

Switch to digital pathology bears fruit

Fully digitising pathology operations has led to greater efficiency, cost savings, and quicker diagnosis for the Laboratory of Pathology East Netherlands (LabPON). The move, made six years ago, is showing measurable benefits and now, the institution is beginning to explore the potential of deep learning computational pathology algorithms, which might push the efficiency gains even further.

Prof Alexi Baidoshvili

Read More

What is Net Zero and what does it mean for events?

As the world considers how it can mitigate climate change, Global Engage has committed to playing its part by reducing the impact of running events. But how to do it? I recently attended an onboarding course organised by ISLA and discovered that “Carbon Neutral” and “Net Zero” are not the same thing!

Read More

Digital Pathology: The Next Hurdles

A Market on the Rise
There has clearly been a surge in interest for digital pathology adoption over the last two years

Read More

Highlights from the 9th Microbiome R&D and Business Collaboration Forum – Europe

It was clear that microbiome companies have been advancing their programs as rapidly as ever, despite the changes brought about by the global pandemic. Service providers—including drug manufacturing organizations—have been busy during the past year, as they continue actively helping diagnostics and therapeutics companies find solutions to advance their products.

Read More

Conversation with Dr Hamid Tizhoosh, Founder of KIMIA Lab and Leading Expert in the Development of Unsupervised AI for Tissue Pathology

What we have to learn from day one when we design these AI applications, is that pathology has to come with us. We cannot just design a network as computer scientists and then go to the pathologists just when we need to validate it. The pathologist has to be with us from the start.

Dr Hamid Tizhoosh

Read More

A Paradigm Change in Skin Health

There has been a rapid acceleration of skin microbiome research. Today about 5% of all microbiome clinical studies and 16% of all probiotic products online are dermatology related. Meanwhile, skin probiotics are growing eight times faster than any other probiotic supplement. In clinical cosmetic studies, the microbiome is the fourth largest category.

Read More

Conversation with one of the founders of modern digital pathology

“Digital pathology has reached the point where if you don’t have digitized slides, you will not be able to do six out of ten things that other pathologists can do today.”

Dr. Anil Parwani

Read More

Switch to digital pathology bears fruit

Fully digitising pathology operations has led to greater efficiency, cost savings, and quicker diagnosis for the Laboratory of Pathology East Netherlands (LabPON). The move, made six years ago, is showing measurable benefits and now, the institution is beginning to explore the potential of deep learning computational pathology algorithms, which might push the efficiency gains even further.

Prof Alexi Baidoshvili

Read More

Digital Pathology: The Next Hurdles

A Market on the Rise
There has clearly been a surge in interest for digital pathology adoption over the last two years

Read More

Highlights from the 9th Microbiome R&D and Business Collaboration Forum – Europe

It was clear that microbiome companies have been advancing their programs as rapidly as ever, despite the changes brought about by the global pandemic. Service providers—including drug manufacturing organizations—have been busy during the past year, as they continue actively helping diagnostics and therapeutics companies find solutions to advance their products.

Read More

Conversation with Dr Hamid Tizhoosh, Founder of KIMIA Lab and Leading Expert in the Development of Unsupervised AI for Tissue Pathology

What we have to learn from day one when we design these AI applications, is that pathology has to come with us. We cannot just design a network as computer scientists and then go to the pathologists just when we need to validate it. The pathologist has to be with us from the start.

Dr Hamid Tizhoosh

Read More

A Paradigm Change in Skin Health

There has been a rapid acceleration of skin microbiome research. Today about 5% of all microbiome clinical studies and 16% of all probiotic products online are dermatology related. Meanwhile, skin probiotics are growing eight times faster than any other probiotic supplement. In clinical cosmetic studies, the microbiome is the fourth largest category.

Read More

Conversation with one of the founders of modern digital pathology

“Digital pathology has reached the point where if you don’t have digitized slides, you will not be able to do six out of ten things that other pathologists can do today.”

Dr. Anil Parwani

Read More

Drug Development for NASH with Fibrosis: Expedited Programs

George Makar spoke at the Global NASH Congress. He gave a regulatory perspective on Drug Development for NASH with Fibrosis. The views were his own. In part one, we explore expedited programs.

Read More

Gut dysbiosis in clinical Huntington’s Disease

Speaking at the recent Microbiome R&D and Business Collaboration Forum, Anthony Hannan explored research using mouse models for brain disorders, particularly in Huntington’s disease (HD), schizophrenia, depression, and anxiety disorders. He also examined the role of gene-environment interactions involving mental activity, physical activity, stressors, and diet.

Read More

Science Communication: challenges to ensure innovation can prove itself scientifically

John Entine is a science journalist who has been writing about sustainability issues in biotechnology for 30 years. He has written numerous books on both population genetic related issues and agricultural biotechnology. Presenting at the Plant Genomics & Gene Editing Congress, he gave his perspective on the communication challenges faced by scientists by looking specifically at gene drives and addressing misunderstandings about what the technology can do and active opposition to it by some environmental groups.

Read More

Why haven’t microbial products been more widely adopted by farmers?

This is a question that drives me each day. Microbial products have been around for a long time; starting with rhizobium in legumes, dating back 125 years. Yet, in the United States, rhizobium inoculants have not been widely adopted by soybean farmers – some indicate less than 15% use overall in the United States. Why?

Read More

From Consortia to Recombinants: opportunities and challenges facing the next generation of microbials

In this blog post I will discuss two themes that I see driving the next generation of live microbe biologicals for agriculture. These are the rational design and delivery of pairs or consortia (which I will define as more than two microbes) and the commercialization of engineered strains.

Read More

What does international collaboration mean for you?

The present COVID-19 crisis has demonstrated the vital need for knowledge sharing across the global science community. We asked three of our speakers what international collaboration means for them as leaders in their fields.

Read More

The Biosynthesis of Cannabinoids

We recently spoke to Jeremy Friedberg, CSO of  LAVVAN, a company pioneering the biosynthesis of cannabinoids. The conversation was recorded as a podcast, which can be found here.

Read More

The grass has never been greener for engineering plant immunity and resilience

Scientific research is always working at the frontiers of knowledge, but plant genomics technologies have had a dramatic impact on plant science even by our standards. The wide availability of sequencing technologies has been a rare step-change that has unlocked knowledge in a way nobody in the field could have imagined twenty years ago. Knowledge which could make a considerable contribution to food security in the face of changing climates.

Read More

New Breeding Techniques: cloning major resistance genes in cereals

Advances in breeding techniques for cereal crops will be a focus at the 8th Plant Genomics and Gene Editing Congress: USA. We asked Burleigh Dodds, an agricultural science publisher, to share an extract from one of their recent publications, ‘Advances in breeding techniques for cereal crops’.

Read More

Plant biotech in Europe: Present and future

Marcel Kuntz is a panellist for the panel discussion on the regulatory landscape for plant biotechnology at the 8th Plant Genomics & Gene Editing Congress: Europe. Here he provides us with some background for the discussion.

Read More

What is Net Zero and what does it mean for events?

As the world considers how it can mitigate climate change, Global Engage has committed to playing its part by reducing the impact of running events. But how to do it? I recently attended an onboarding course organised by ISLA and discovered that “Carbon Neutral” and “Net Zero” are not the same thing!

Read More

Multiplex and high fidelity: the potential of qPCR

Ahead of the qPCR & Digital PCR Congress, we sat down with David Zhang to talk about his work with PCR as a diagnostic platform.

Read More

Examining Blockchain Systems & Designing Smart Contracts

The blockchain has the potential to enable the collaboration between patients, researchers, and care providers to provide individualised care for patients, but how can this technology be harnessed in a practical way?

This was one of the key questions that was asked at the Blockchain in Healthcare Congress and we had the pleasure of welcoming an array of expert speakers from pharma, academia, and industry to provide the answer.

Read More

The role of extrinsic motivation in sports and physical activity

Motivation is one of the most significant psychological concepts in many areas of life – from work and education to achieving personal goals. In sports and physical activity, motivation plays an especially important part due to the fact that, to millions of people worldwide, staying fit and active is not an obligation or a professional prerequisite, but rather a personal goal. Blockchain technology, together with elements of gamification, may actually help people achieve this goal.

Read More

Conciliating Blockchain and GDPR

Aurélie Bayle is a Data Protection Officer at be-ys: a role she considers to be at the heart of the new legal framework for any company.

Before GDPR came into effect on 25th May 2018, she was working towards global compliance, which involved completing all the steps given by the Article 29 Data Protection Working Party, an advisory board made up of a representative from the data authority of each EU Member State, the European Data Protection Supervisor, and the European Commission. Her duties have included auditing the structures and processes, preparing the data protection impact assessments, checking the compliance of processing activities, analysing the risks of the processing in the medical area, preparing new processes and policies about data protection, and asking data processors about their own compliance.

Read More

When Blockchain Meets the Right to be Forgotten: Technology Versus Law

Over the past few years, the popularity of the blockchain and cryptocurrencies has increased and has reached important notoriety, not only in scientific and IT journals, but also in the media. Although there are many kinds of cryptocurrencies in circulation nowadays, the most popular is Bitcoin.

Read More

Supporting Blockchain Startups: An Open Letter from Katherine Merton

Dear colleagues,

The blockchain technology market is expected to grow to 2.3 billion US dollars by 2021, from 339.5 million US dollars in 2017. [1] With an annual growth rate of 61.5%, it is one of the fastest growing technologies in the healthcare industry.

Read More

The Big List of Microfluidics Companies & Investors

The microfluidic-based devices market has been growing since 2014 due to the increasing point of care testing demand and the miniaturisation of microfluidic chips. 

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Archive